Background: Although the clinical course of the COVID-19 in adults has been extensively described, the impact of the co-detection of SARS-CoV-2 and rhinovirus on severity outcomes is not understood.
Objectives: This study aimed to compare the risk of hospitalization of outpatients with COVID-19 with and without the co-detection of rhinovirus in southern Brazil. Secondarily, such risk was also compared between all individuals with COVID-19 and those with single rhinovirus infection.
Study Design: Outpatients (>18 years) with acute signs of cough, fever, or sore throat were prospectively enrolled at two emergency departments from May to September 2020. Sample collection was performed to detect SARS-CoV-2 and other 20 respiratory pathogens. Participants were followed for 28 days through telephone interviews.
Results: 1,047 participants were screened and 1,044 were included. Of these, 4.9% were lost during follow-up, and 993/1,044 (95.1%) were included in severity-related analysis. Rhinovirus was the most prevalent pathogen (25.0%, 248/993), followed by SARS-CoV-2 (22.6%, 224/993), with coinfection of these two viruses occurring in 91/993 (9.2%) participants. The risk of COVID-19-related hospitalizations were not different between individuals with and without co-detection of rhinovirus (9.9% vs. 7.6%, respectively, P = 0.655). Conversely, subjects with COVID-19 had a higher hospitalization risk than single rhinovirus infection (8.3 vs 0.4%, respectively, P < 0.001).
Conclusions: The co-detection of SARS-CoV-2 and rhinovirus did not change the risk of hospitalizations in adults. Furthermore, COVID-19 was more severe than single rhinovirus infection.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170614 | PMC |
| http://dx.doi.org/10.1016/j.jcv.2022.105197 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Seasonal shifts in respiratory pathogen co-infections and the associated differential induction of cytokines in children.
Cytokine
December 2024
Center for Translational Medicine, Wuhan Jinyintan Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei 430023, China; Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address:
In the post-pandemic era, research on respiratory diseases should refocus on pathogens other than the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Respiratory pathogens, highly infectious to children, with to different modes of infection, such as single-pathogen infections and co-infections. Understanding the seasonal patterns of these pathogens, alongside identifying single infections and co-infections and their impact on the pediatric immune status, is crucial for clinical diagnosis, treatment, and prognosis in children.
View Article and Find Full Text PDFMulticenter Evaluation of the QIAstat-Dx and the BioFire Multiplex Panel Tests for the Detection of Respiratory Pathogens.
J Med Virol
December 2024
Clinical Virology, University Hospital Basel, Basel, Switzerland.
Syndromic multiplex panel testing enables simultaneous detection of multiple respiratory pathogens, but limited data is available on the comparative diagnostic performance of different testing systems. In this multicenter prospective study, we aimed to compare the QIAstat-Dx Respiratory Panel 2.0 (QIAstat-Dx-RP2.
View Article and Find Full Text PDFLower respiratory tract infections following respiratory syncytial virus monoclonal antibody nirsevimab immunization versus placebo: Analysis from a Phase 3 randomized clinical trial (MELODY).
Clin Infect Dis
December 2024
Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Background: Nirsevimab is an extended half-life, highly potent neutralizing monoclonal antibody against the respiratory syncytial virus (RSV) fusion protein, with efficacy in preventing RSV-associated medically attended (MA) lower respiratory tract infection (LRTI) in infants and medically vulnerable children (aged ≤24 months). This post-hoc exploratory analysis examined the incidence of LRTI from RSV and other respiratory pathogens during a 2:1 randomized, double-blind, placebo-controlled, phase 3 study of nirsevimab, in healthy-term and late-preterm (i.e.
View Article and Find Full Text PDFPrevalence of respiratory pathogens among hospitalised patients with acute respiratory infection during and after the COVID-19 pandemic in Shijiazhuang, China.
Front Cell Infect Microbiol
December 2024
Hebei Key Laboratory of Basic Medicine for Diabetes, Shijiazhuang Second Hospital, Shijiazhuang, Hebei, China.
Background: The COVID-19 pandemic and the resulting non-pharmaceutical interventions (NPIs) have led to changes in the epidemiology of other respiratory pathogens. This study was conducted to explore the epidemiological characteristics of 13 respiratory pathogens, including 11 respiratory viruses and 2 non-classical microorganisms, in hospitalised patients with acute respiratory tract infections (ARTIs) and to compare the prevalence of respiratory pathogens during and after the COVID-19 pandemic.
Methods: We conducted a single-centre retrospective study involving 8979 patients with ARTIs in Shijiazhuang City from December 2019 to December 2023.
Precision Diagnosis of Viral Respiratory Infections: Unleashing the Power of Multiplex Polymerase Chain Reaction (PCR) for Enhanced Infection Management.
Cureus
November 2024
Microbiology, All India Institute of Medical Sciences, Rishikesh, Rishikesh, IND.
Background: Viruses are key agents causing respiratory illnesses, creating significant public health challenges worldwide. Timely identification of the responsible pathogen is crucial for effective patient management. Conventional virus detection methods in laboratories are often laborious and time-consuming, prompting the need for more efficient diagnostic techniques.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!